logo-loader
Imugene Ltd

Imugene appoints venture capital executive to board

The company finished the March quarter with $21 million in the bank.

three empty board seats
It is it well-positioned to progress its commercial and clinical milestones

Imugene Ltd (ASX:IMU) has appointed Dr Jens Eckstein as a non-executive director to its board effective as of today.

Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.

He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.

READ: Imugene to present new data from HER-Vaxx cancer vaccine phase 1b trial

Imugene’s executive chairman Paul Hopper said: “Imugene continues to attract a world class team.

“We welcome Dr Eckstein to the board and look forward to working together to advance our highly promising cancer immuno therapy pipeline.”

Strong pipeline of cancer vaccines in development

The company has a strong pipeline of cancer vaccines in development.

Quick facts: Imugene Ltd

Price: $0.02

Market: ASX
Market Cap: $83.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development...

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.   The company had a pre-investigational new drug meeting with the US Food and Drug Administration...

on 20/3/19

2 min read